BTG (BTG)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 27.4 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.74 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Mar | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | ||||||||||
| Operating Profit | £m | ||||||||||
| Net Profit | £m | ||||||||||
| EPS Reported | p | ||||||||||
| EPS Normalised | p | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | p | ||||||||||
| Capex ps | p | ||||||||||
| Free Cashflow ps | p | ||||||||||
| Dividends | |||||||||||
| Dividend ps | p | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | £m | ||||||||||
| Working Capital | £m | ||||||||||
| Net Fixed Assets | £m | ||||||||||
| Net Debt | £m | ||||||||||
| Book Value | £m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | p | +31.7% | |||||||||
FINANCIAL BRIEF: For the six months ended 30 September 2012, BTG plc revenues increased 30% to L143.4M. Net income increased 44% to L18.3M. Revenues reflect Speciality Pharmaceutcals segment increase of 30% to L67.5M, Licensing & Biotechnology segment increase of 28% to L58.2M, Interventional Medicine segment increase of 35% to L17.7M, USA segment increase of 35% to L128.6M, UK segment increase of 48% to L6.5M, Other segment increase of 11% to L2M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 4 | 2 | 3 |
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its products include a treatment for snakebites, antidotes to treat toxicity associated with medicines used for heart conditions and cancer, and interventional oncology products that are used to treat patients with liver or prostate tumours. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are embolisation and drug-eluting beads used primarily to treat patients with liver tumours and brachytherapy products used mainly for early-stage prostate cancer. Licensing & Biotechnology business area consists of licensed products and programmes and generates royalties for BTG. Its commercial sold products include CroFab (crotalidae polyvalent immune fab (ovine)) and DigiFab (digoxin immune fab (ovine)).
Directors: Louise Makin (CEO) , Rolf Soderstrom (CFO) , Paul Mussenden (Secy.) ,
No. of Employees: 498 No. of Shareholders: 10,727
| Last Annual | March 31st, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 328,207,711 |
| Free Float | 321.8m (98.1%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE 350 Act , FTSE Lower Yield , FTSE 250 Mid , FT350 Phar & Bio , FTSE Techmark Focus , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom |
| Web | http://www.btgplc.com |
| Phone | +44 20 75750000 |
| Contact | Andy Burrows (Director - Investor Relations) |
| Registrar | Capita Registrars |
| Auditors | KPMG Audit PLC |
| 30th Apr | Total Voting Rights |
| 15th Apr | Holding(s) in Company |
| 15th Apr | Holding(s) in Company |
| 12th Apr | Varisolve? NDA accepted for full review by FDA |
| 4th Apr | Close period update |
| 2nd Apr | Blocklisting Interim Review |
Recent ↓
